Lumos Diagnostics Holdings Ltd.ASX: LDX

Lumos Secures 100% US Medicare Reimbursement for FebriDx

· Issued by Lumos Diagnostics Holdings Ltd.

Filed with ASX · · 3 pages · English

Summary by 6ix AI

Lumos Diagnostics Holdings Ltd. has announced that it has secured full Medicare reimbursement recognition for its product FebriDx from all Medicare Administration Contractors in the U.S. This achievement allows for reimbursement at a specified rate per test and is expected to facilitate broader adoption of FebriDx across the U.S. healthcare system. The company will now focus on assisting the contractors in developing written policies to streamline reimbursement claims management. This recognition is significant as it also benefits Medicare Advantage and Medicaid plans, which often reference Medicare fee schedules for their own reimbursement frameworks.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Lumos Diagnostics Holdings Ltd. on 6ix

Story so far

Earlier from Lumos Diagnostics

Later from Lumos Diagnostics

All Lumos Diagnostics news releases